|
Market Closed -
Nasdaq
21:00:00 13/02/2026 GMT
|
5-day change
|
1st Jan Change
|
|
196.52 USD
|
+0.52%
|
 |
-2.32%
|
+11.67%
|
|
02-13 |
Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
| | |
02-12 |
Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…
|  | |
02-11 |
Biogen Inc. Announces Board Changes
|
CI
| |
02-11 |
Biogen Announces Board Chair Transition
|
GL
| |
02-10 |
Biogen Insider Sold Shares Worth $531,548, According to a Recent SEC Filing
|
MT
| |
02-10 |
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating
|
MT
| |
02-09 |
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says
|
MT
| |
02-09 |
All or Nothing Week
| | |
02-09 |
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating
|
MT
| |
02-09 |
HC Wainwright Adjusts Price Target on Biogen to $228 From $194, Maintains Buy Rating
|
MT
| |
02-09 |
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating
|
MT
| |
02-09 |
Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating
|
MT
| |
02-09 |
Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating
|
MT
| |
02-09 |
Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating
|
MT
| |
02-09 |
Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating
|
MT
| |
02-09 |
Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating
|
MT
| |
02-09 |
TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating
|
MT
| |
02-09 |
Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis…
| | |
02-09 |
Bioarctic AB for Subcutaneous Formulation of Leqembi Designated for Priority Review in China
|
CI
| |
02-09 |
Biogen : Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
|
PU
| |
02-09 |
Biogen says biologics license application for subcutaneous formulation of Leqembi for treatment of early Alzheimer's disease designated for Priority Review in China
|
RE
| |
02-06 |
Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating
|
MT
| |
02-06 |
Biogen Inc., Q4 2025 Earnings Call, Feb 06, 2026
| | |
02-06 |
Biogen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
02-06 |
Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
